NYX 2925

Drug Profile

NYX 2925

Alternative Names: NYX-2925

Latest Information Update: 19 May 2017

Price : $50

At a glance

  • Originator Aptinyx
  • Class Small molecules
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neurological disorders
  • Preclinical Neuropathic pain

Most Recent Events

  • 17 May 2017 Pharmacodynamics data from a preclinical trial in Neuropathic pain released by Aptinyx
  • 01 Mar 2017 Aptinyx completes a phase I trial in Neurological disorders in USA (PO) (NCT02834741)
  • 26 Sep 2016 Pharmacodynamics and pharmacokinetics data from a preclinical study in Neurological indications presented at the 16th World Congress on Pain (WCP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top